Skip to content

Author

S. Signoretti

We have 2 of 15 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

Final results and predictive biomarkers of response and long-term outcomes with first-line pembrolizumab monotherapy in advanced renal cell carcinoma in the phase II KEYNOTE-427 study.

These results show that pembrolizumab is a highly active agent in ccRCC and nccRCC and insights from the comprehensive analysis of RCC tumor molecular components and ctDNA may facilitate progress toward effective, biomarker-driven precision treatment in advanced RCC.

D. McDermott, S. Signoretti, J. Lee et al. · 1 citation
Open access Sep 2026

75 Transcriptional Correlates of ARNT Expression and its Impact on Survival Outcomes in Clear-Cell Renal Cell Carcinoma (ccRCC)

Across three cohorts, higher ARNT expression correlated with higher BHS, and a consistent correlation was observed between ARNT and EPAS1 and HIF1A expressions, and a consistent correlation was observed between ARNT and EPAS1 expressions.

Wassim Daoud Khatoun, Ali Hajj Ali, Eddy Saad et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.